A trial for adults with major depressive disorder failed to significantly reduce the severity of the disorder compared with a placebo, according to the sponsor Neurocrine Biosciences Inc of San Diego, US. The Phase 2 study enrolled 73 adults with a diagnosis of major depressive disorder and an inadequate response to at least one antidepressant in their regular treatment paradigm. The product, NBI-1070770, is a negative allosteric modulator of a subunit of a receptor that plays a role in the working memory. Participants received the drug or a placebo for four weeks.
